Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...